BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Montigen Pharmaceuticals Inc. Closes $5.2M Series A Financing


10/19/2005 5:10:11 PM

SALT LAKE CITY, May 13 /PRNewswire/ -- Montigen Pharmaceuticals Inc., a biopharmaceutical company engaged in the identification and development of novel therapeutics to treat cancer and other serious human diseases, today announced that it has closed a $5,200,000 Series A financing. Terms were not disclosed. D. McKay Anderson, Montigen's Chief Executive Officer, commented: "Completion of this financing provides Montigen with the resources to advance our lead compound into Phase I clinical trials, and further bolster the capacity of our proprietary discovery and development engine."

Montigen is in late-stage pre-clinical testing with its lead drug candidate MP-470, a multi-targeted novel small molecule tyrosine-kinase inhibitor. The company is also developing MP-235, a small molecule inhibitor of Aurora-A kinase.

"This funding enables us to complete pre-clinical development of MP-470, and further advance MP-235," said Dr. David Bearss, co-founder and Chief Scientific Officer of Montigen. "In parallel we will continue to progress our internal development technologies and robust pipeline, focusing on the optimization of additional small molecule inhibitors discovered by Montigen scientists."

About Montigen Pharmaceuticals

Montigen is a drug discovery and development company dedicated to alleviating human suffering by developing novel therapeutics to treat and cure life-threatening diseases. Montigen utilizes its revolutionary CLIMB(TM) drug development platform and is developing two promising compounds: MP235, a novel small molecule inhibitor of Aurora-2 kinase, a gene amplified in most human cancer cells; and MP470, a small molecule PDGF/C-kit receptor, both tyrosine-kinase receptors that play critical roles in transducing growth signals to cancer cells.

Montigen is a privately held company headquartered in Salt Lake City, Utah. For additional information, please visit the company's website at http://www.montigen.com/.

Montigen Pharmaceuticals Inc.

CONTACT: D. McKay Anderson, CEO of Montigen Pharmaceuticals, Inc.,+1-801-478-1645, or fax, +1-801-466-3892, danderson@montigen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES